ClinicalTrials.gg
CompletedNCT03484819Updated Mar 3, 2025Results posted

Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

A Phase 2 interventional study of Copanlisib Hydrochloride and Nivolumab in Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma and Refractory Diffuse Large B-Cell Lymphoma, sponsored by National Cancer Institute (NCI). Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-03.

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 14 studies testing nivolumab in Lymphoma, Large B-Cell, Diffuse — 1 open to participants now, 4 under way, none of them phase 3. Nivolumab · Lymphoma, Large B-Cell, Diffuse.

Enrollment
9th of 14
12 · median 18
Started
2019
with 3 others
Phase 2
4 of 14
none open now
Registered
5th of 14
by date
Lead sponsor
3 of 14
National Cancer Institute (NCI)

Among the 14 studies testing nivolumab in Lymphoma, Large B-Cell, Diffuse, this one is the 9th largest by enrollment, is one of 4 that started in 2019, is one of 4 in phase 2, and was the 5th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

1 of the 14 studies testing nivolumab in Lymphoma, Large B-Cell, Diffuse is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing nivolumab in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This phase II trial studies how well copanlisib hydrochloride and nivolumab work in treating patients with diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma that has come back (recurrent) or does not responded to the treatment (refractory). Copanlisib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving copanlisib hydrochloride and nivolumab may work better in treating patients with diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma compared to standard of care.

Read the detailed description

PRIMARY OBJECTIVE:

I. To assess overall response rate (ORR) defined as complete response rate (CR) plus partial response rate (PR) (ORR = CR + PR) of the combination of copanlisib hydrochloride (copanlisib) and nivolumab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL).

SECONDARY OBJECTIVES:

I. To evaluate the safety of the combination of nivolumab and copanlisib in patients with relapsed/refractory DLBCL and PMBCL.

II. To determine the progression free survival, duration of response, complete response rate and overall survival of the combination of copanlisib and nivolumab in patients with relapsed or refractory DLBCL and PMBCL.

CORRELATIVE STUDY OBJECTIVES:

I. To characterize the effects of the copanlisib and nivolumab combination regimen on tumor cells, tumor microenvironment and the immune response in relapsed/refractory DLBCL and PMBCL.

II. To assess predictors of response of the combination in relapsed/refractory DLBCL and PMBCL.

OUTLINE:

Patients receive copanlisib hydrochloride intravenously (IV) over 1 hour on days 1, 8 and 15 of cycles 1-8 and days 1 and 15 of subsequent cycles. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 of cycles 1-8 and on day 1 of subsequent cycles. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for up to 100 days.

03

Conditions studied

  • Recurrent Diffuse Large B-Cell Lymphoma
  • Recurrent Primary Mediastinal Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Refractory Primary Mediastinal Large B-Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have a histopathologically confirmed diagnosis of diffuse large B-cell lymphoma (DBLCL) or primary mediastinal large B-cell lymphoma
  • Patients must have , defined as at least one lesion that is >= 15 mm (>= 1.5 cm) in the longest axis on cross-sectional imaging and measurable in two perpendicular dimensions per spiral computed tomography (CT) scan or positron-emission tomography (PET)-CT scan
  • Patients must have disease that is recurrent or to standard therapy; patients must have failed front-line therapy and declined or are not candidates for stem cell transplant (ASCT) or have failed prior ASCT
  • (ECOG) performance status of 0, 1 or 2
  • of greater than 12 weeks
  • White blood cell (WBC) >= 2000/mm\^3
  • (ANC) >= 1000/mm\^3
  • count >= 100,000/mm\^3
  • > 9.0 g/dL
  • Total =\< 1.5 x (ULN) (except patients with Gilbert syndrome, who can have total bilirubin \< 3.0 mg/dL)
  • (AST) =\< 2.5 x ULN
  • Serum creatinine =\< 2.0 mg/dL OR calculated (CrCl) >= 30 mL/min (if using the Cockcroft-Gault formula)
  • Negative urine or serum pregnancy test for females of child bearing potential within 7 days prior to registration

    • The effects of copanlisib and nivolumab on the developing human fetus are unknown; for this reason, and because the study drugs used in this trial are known to be teratogenic, females of must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and for 5 months after the last dose of study drug; males who are the sexual partners of a female of child-bearing potential must use any contraceptive method with a failure rate of less than 1% per year for the duration of study participation and for a period of 7 months after the last dose of study drug; these periods of required use of contraception have been calculated using the upper limit of the half-life for nivolumab (25 days) and are based on the protocol requirement that females of child-bearing potential use contraception for 5 months and males who are the sexual partners of females of child-bearing potential use contraception for 7 months
    • Females must not be breast-feeding for 1 month after last dose
    • Females of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of nivolumab
    • A female of child-bearing potential is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not ; menopause is defined clinically as 12 months of amenorrhea in a female over 45 in the absence of other biological or physiological causes; in addition, females under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL
    • Females who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) and azoospermic males do not require contraception
    • Should a female of child-bearing potential become pregnant or suspect she is pregnant while she or her partner is participating in this study, she (or the participating partner) should inform the treating physician immediately
  • Ability to understand and the willingness to sign a written document

Exclusion criteria

Exclusion Criteria:

  • Any high grade B-cell lymphoma
  • Patients who have had chemotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C), anticancer antibodies within 4 weeks, radio or toxin immunoconjugates within 2 weeks, radiation therapy within 3 weeks or major surgery within 2 weeks prior to entering the study

    • Palliative (limited-field) radiation therapy is permitted if the patient has additional to assess response of therapy
  • Patients who have not recovered to grade 1 or less from any adverse events due to agents administered more than 4 weeks earlier (excluding alopecia)
  • Patients who are receiving any other agents
  • Patients should be excluded if they have had prior treatment with a Pi3 kinase inhibitor, , anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways; Note: Patients who previously received CART therapy and progressed will be eligible
  • Patients who have received stem cell transplant (ASCT) =\< 8 weeks prior to the first dose of study drug or no adequate count recovery
  • Patients with a prior history of allogeneic stem cell or solid organ transplantation
  • Patients with evidence of active disease in the central nervous system (CNS) defined as either the presence of active lesions on magnetic resonance imaging (MRI) obtained within 4 weeks of registration or progressive neurological decline; patients with primary central nervous system (CNS) lymphoma who develop systemic recurrence following standard therapy may be included as long as no active CNS disease is present at the time or enrollment; similarly, patients with secondary involvement of the CNS from a systemic lymphoma may be included as long as the CNS disease has been optimally treated and they demonstrate no evidence of active CNS disease
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to copanlisib and/or nivolumab
  • History of severe reaction to any monoclonal antibody
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, non-healing wound or ulcer, or bone fracture, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, known history of atrial fibrillation except those with 1 event that has resolved more than 1 year ago without recurrence, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study because copanlisib and nivolumab are agents with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with copanlisib or nivolumab, breastfeeding should be discontinued for 1 month after last dose if the mother is treated with copanlisib or nivolumab
  • Patients with (HIV):

    • Patients with HIV are eligible for the study provided they meet the other protocol criteria in addition to the following:

      • Undetectable HIV load by standard polymerase chain reaction (PCR) clinical assay
      • Absolute of >= 200 mm\^3
      • Willing to maintain adherence to combination antiretroviral therapy
      • No history of acquired immunodeficiency syndrome (AIDS) defining condition (other than lymphoma or CD4 cell count \< 200 mm\^3)
      • Likely to have near normal lifespan if not for the presence of lymphoma
    • The patients with evidence of virus (HBV) are eligible provided there is minimal hepatic injury and the patient has undetectable HBV on suppressive HBV therapy; patient must be willing to maintain adherence to HBV therapy
    • Patients with previously treated and eradicated virus (HCV) who have minimal hepatic injury are eligible
  • Patients with active disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic , should be excluded; these include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease; patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible; patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
  • Patients are permitted to enroll if they have vitiligo, type 1 diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event); however, patients with uncontrolled type I or II diabetes mellitus will be excluded; uncontrolled diabetes is defined as (HbA1c) > 8.5%
  • Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =\< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =\< 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
  • Patients who have had evidence of active or acute diverticulitis, intra-abdominal abscess, and gastrointestinal (GI) obstruction which are known risk factors for bowel perforation should be evaluated for the potential need for additional treatment before coming on study
  • Patients with other active =\< 3 years prior to registration for which active treatment is required must be excluded; patients with composite lymphomas that have a non-B-cell component must be excluded

    • EXCEPTIONS: Non-melanotic skin cancers or carcinoma-in-situ of the cervix
  • Copanlisib is primarily metabolized by ; therefore, the concomitant use of strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir), and strong inducers of CYP3A4 (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, St. John's Wort) are not permitted from 14 days prior to enrollment until the end of the study

    • Note: Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference; as part of the enrollment/ procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product; other medications that are prohibited while on copanlisib treatment:

      • Herbal medications/preparations (except for vitamins)
      • Anti-arrhythmic therapy other than beta blockers or digoxin
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Treatment (copanlisib hydrochloride, nivolumab)

    Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8 and 15 of cycles 1-8 and days 1 and 15 of subsequent cycles. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 of cycles 1-8 and on day 1 of subsequent cycles. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

    Drug: Copanlisib Hydrochloride · Biological: Nivolumab

Interventions

  • Given IV

    Also known as: 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2), Aliqopa, BAY 80-6946 Dihydrochloride, BAY-80-6946 Dihydrochloride, Copanlisib Dihydrochloride

  • BiologicalNivolumab

    Given IV

    Also known as: ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    Will be estimated by the number of successes divided by the total number of evaluable patients. A success is defined as a patient that reports a confirmed complete or partial response according to Lugano criteria.

    Time frame: 23 months

Secondary outcomes

  1. Number of Grade 3+ Adverse Events

    The number of patients experiencing one or more grade 3+ adverse events will be reported.

    Time frame: 24 months

  2. Progression Free Survival

    Will be estimated using the method of Kaplan-Meier.

    Time frame: 12 months

  3. Duration of Response (DOR)

    Will be estimated using the method of Kaplan-Meier. Patients reporting a confirmed or unconfirmed, partial or complete response are included in analysis.

    Time frame: 12 months

  4. Overall Survival Time

    Will be estimated using the method of Kaplan-Meier.

    Time frame: 24 months

Other outcomes

  1. Lymph3Cx Cell-of-Origin (COO) Molecular Subtyping Assay for Primary Mediastinal B Cell Lymphoma (PMBCL) and Diffuse Large B Cell Lymphoma (DLBCL) Subtypes

    Time frame: Up to 5.5 years

07

Results

Posted Jan 23, 2024

Participant flow

Participant flow — Overall Study
MilestoneTreatment (Copanlisib Hydrochloride, Nivolumab)
Started12
Completed0
Not completed12
Withdrew: Death2
Withdrew: Adverse event2
Withdrew: Physician decision1
Withdrew: Withdrawal by subject2
Withdrew: Disease progression4
Withdrew: Complicating condition1

Outcome measures

PrimaryObjective Response Rate

Will be estimated by the number of successes divided by the total number of evaluable patients. A success is defined as a patient that reports a confirmed complete or partial response according to Lugano criteria.

Time frame:
23 months
Reported as:
Count of participants · Participants
Objective Response Rate
ParticipantsTreatment (Copanlisib Hydrochloride, Nivolumab)
Objective Response Rate3
SecondaryNumber of Grade 3+ Adverse Events

The number of patients experiencing one or more grade 3+ adverse events will be reported.

Time frame:
24 months
Reported as:
Count of participants · Participants
Number of Grade 3+ Adverse Events
ParticipantsTreatment (Copanlisib Hydrochloride, Nivolumab)
Number of Grade 3+ Adverse Events10
SecondaryProgression Free Survival

Will be estimated using the method of Kaplan-Meier.

Time frame:
12 months
Reported as:
Median · months
Progression Free Survival
monthsTreatment (Copanlisib Hydrochloride, Nivolumab)
Progression Free Survival2.9 (2.1 to NA)
SecondaryDuration of Response (DOR)

Will be estimated using the method of Kaplan-Meier. Patients reporting a confirmed or unconfirmed, partial or complete response are included in analysis.

Time frame:
12 months
Reported as:
Median · months
Duration of Response (DOR)
monthsTreatment (Copanlisib Hydrochloride, Nivolumab)
Duration of Response (DOR)NA (2.8 to NA)
SecondaryOverall Survival Time

Will be estimated using the method of Kaplan-Meier.

Time frame:
24 months
Reported as:
Median · months
Overall Survival Time
monthsTreatment (Copanlisib Hydrochloride, Nivolumab)
Overall Survival Time13.2 (3.6 to NA)
Other pre-specifiedLymph3Cx Cell-of-Origin (COO) Molecular Subtyping Assay for Primary Mediastinal B Cell Lymphoma (PMBCL) and Diffuse Large B Cell Lymphoma (DLBCL) Subtypes
Time frame:
Up to 5.5 years

Results for this outcome have not been posted.

Adverse events

Collected over 24 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment (Copanlisib Hydrochloride, Nivolumab)7/12 (58.3%)10/12 (83.3%)12/12 (100%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventTreatment (Copanlisib Hydrochloride, Nivolumab)
Atrial fibrillationCardiac disorders4/12
HypertensionVascular disorders4/12
Neutrophil count decreasedInvestigations3/12
White blood cell decreasedInvestigations3/12
HyperglycemiaMetabolism and nutrition disorders2/12
AnemiaBlood and lymphatic system disorders1/12
Atrial flutterCardiac disorders1/12
Cardiac arrestCardiac disorders1/12
ConstipationGastrointestinal disorders1/12
IleusGastrointestinal disorders1/12
Most frequent other events
Showing 10 of 82
Most frequent other events
EventTreatment (Copanlisib Hydrochloride, Nivolumab)
Lymphocyte count decreasedInvestigations7/12
NauseaGastrointestinal disorders6/12
White blood cell decreasedInvestigations5/12
HyperglycemiaMetabolism and nutrition disorders5/12
HypomagnesemiaMetabolism and nutrition disorders5/12
AnemiaBlood and lymphatic system disorders4/12
DiarrheaGastrointestinal disorders4/12
FatigueGeneral disorders4/12
Neutrophil count decreasedInvestigations4/12
Platelet count decreasedInvestigations4/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treatment (Copanlisib Hydrochloride, Nivolumab)
Mean71.3 ± 9.48
Sex: Female, Male
Sex: Female, Male(Participants)Treatment (Copanlisib Hydrochloride, Nivolumab)
Female5
Male7
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment (Copanlisib Hydrochloride, Nivolumab)
Hispanic or Latino0
Not Hispanic or Latino12
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment (Copanlisib Hydrochloride, Nivolumab)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White11
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Treatment (Copanlisib Hydrochloride, Nivolumab)
United States12
ECOG Performance Status
ECOG Performance Status(Participants)Treatment (Copanlisib Hydrochloride, Nivolumab)
03
16
23
08

Study locations

15 sites
  • University of Alabama at Birmingham Cancer Center
    Birmingham, Alabama 35233, United States
  • University of Iowa/Holden Comprehensive Cancer Center
    Iowa City, Iowa 52242, United States
  • HaysMed
    Hays, Kansas 67601, United States
  • University of Kansas Cancer Center
    Kansas City, Kansas 66160, United States
  • The University of Kansas Cancer Center - Olathe
    Olathe, Kansas 66061, United States
  • Ascension Via Christi - Pittsburg
    Pittsburg, Kansas 66762, United States
  • Salina Regional Health Center
    Salina, Kansas 67401, United States
  • University of Kansas Health System Saint Francis Campus
    Topeka, Kansas 66606, United States
  • University of Kansas Hospital-Westwood Cancer Center
    Westwood, Kansas 66205, United States
  • University of Kentucky/Markey Cancer Center
    Lexington, Kentucky 40536, United States
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
  • University Health Truman Medical Center
    Kansas City, Missouri 64108, United States
  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
    Lebanon, New Hampshire 03756, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • Huntsman Cancer Institute/University of Utah
    Salt Lake City, Utah 84112, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Nov 2022, 35 months.

Results were first posted in Jan 2024, 1 year 2 months after primary completion.

Of 210 non-industry phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's 35 months is below that.

Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2018
First posted
Apr 2, 2018
StartActual
Dec 13, 2019
Primary completionActual
Nov 18, 2022
CompletionActual
Aug 14, 2024
Results first posted
Jan 23, 2024
Last update
Mar 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03484819
Responsible party
Sponsor
First posted
Apr 2, 2018
Start date
Dec 13, 2019
Primary completion
Nov 18, 2022
Completion
Aug 14, 2024
Results posted
Jan 23, 2024
Last update
Mar 3, 2025

Study contacts

Nabila N Bennani
principal investigator · Mayo Clinic Cancer Center LAO

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Copanlisib hydrochloride · Nivolumab

Start the discussion